{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Orange T","title":"What's Changing in Biotech: Capital, Reimbursement, and AI, with Audrey Greenberg","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/eccb23fa\"></iframe>","width":"100%","height":180,"duration":2968,"description":"Description:\nThe economics of biotech have changed.\nCapital is more expensive than it was a few years ago. Reimbursement is entering the conversation earlier. The newest therapies are also the hardest to manufacture and pay for. And AI is starting to move from promise into practical use across the industry.\nOn this episode of The Orange T, Stephen M. Perry talks with biotech entrepreneur and investor Audrey Greenberg about what that shift means for the companies building the next generation of therapies.\nThey discuss three forces reshaping the industry:\nWhy scientific innovation alone is no longer enough to make a therapy commercially successful\nHow manufacturing costs and reimbursement pressure are reshaping advanced therapies\nWhy investors are becoming more sophisticated about risk and return\nGreenberg also shares what she is seeing as a venture partner at Mayo Clinic, including how AI is being used to analyze complex patient data, support clinical decisions and potentially change how risk is financed in early-stage drug development..\nAbout Audrey Greenberg\nAudrey Greenberg is a biotech entrepreneur, investor and venture partner at Mayo Clinic. She previously co-founded and scaled Center for Breakthrough Medicines, a contract development and manufacturing organization focused on cell and gene therapies.\n\nAbout The Orange T\nThe Orange T explores what it means to be a T-shaped professional: developing deep expertise while building the breadth needed to connect ideas, disciplines and people.\n🎧 Subscribe to The Orange T for conversations about biotechnology, healthcare, investment, innovation and the forces shaping the future of life sciences.","thumbnail_url":"https://img.transistorcdn.com/iGggOLilZyybzXSLfm_fO-Ay8j8bQ_vHtJb7WAF2_ag/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kZDM5/MmE1M2MzZDc2YjE5/YWViZWQ0NTBjMjk2/MTgyNi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}